Changes with in vitro Activation of the B Cell Panel Antigens
With exposure to specific antigenic or mitogenic stimuli, B cells proliferate and subsequently differentiate into antibody-secreting cells. The initial events which accompany activation include an increase in cell size, augmented DNA and RNA synthesis, and changes in cell surface structures. The expression of surface immunoglobulin (SIg) and la, the classical surface markers of B cells, has been extensively studied during in vitro stimulation. Upon activation, resting B cells which express IgM and/or IgD will lose SIgD, and then no longer express membrane Ig or switch to the expression of other isotypes (1). Similarly, resting B cells continue to express la after activation until the plasma cell stage (2). In our laboratory, utilizing a panel of monoclonal antibodies directed against B cell differentiation antigens, we have noted changes in the cell surface pheno- type of resting B cells with activation. Two B cell-restricted antigens, B1 and B4, have been observed to be expressed on resting and activated B cells, and lost prior to the terminal stages of differentiation (3,4). The B2 antigen, present on resting cells is lost during the early stages of activation (4,5). We and others have described additional antigens which are not expressed on resting B cells but only appear with activation. These acti-vation antigens include B-LAST 1 (6), B5 (7), interleukin-2 receptor (IL- 2R) (8,9), BB1 (10), 4F2 (11), and the transferrin receptor (11).
KeywordsAlbumin Lymphoma Leukemia Germinal Pyruvate
Goding, J.W., D.W. Scott, and J.E. Layton. 1977. Genetics, cellular expression and function of IgD and IgM receptors. Immunol. Rev.
: 152.PubMedCrossRefGoogle Scholar
Halper, J.S., S.M. Fu, C.Y. Winchester, and H.G. Kunkel. 1978. Patterns of expression of human la-like antigens during the terminal stage of B cell development. J. Immunol.
: 1480.PubMedGoogle Scholar
Nadler, L.M., K.C. Anderson, G. Marti, M. Bates, E. Park, J.F. Daley, and S.F. Schlossman. 1983. B4, a human B lymphocyte-associated antigen ex-pressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol.
: 244.PubMedGoogle Scholar
Boyd, A.W., K.C. Anderson, A.S. Freedman, D.C. Fisher, B. Slaughenhoupt, S.F. Schlossman, and L.M. Nadler, 1985. Studies of in vitro
activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody J. Immunol
: 1516.PubMedGoogle Scholar
Stashenko, P., L.M. Nadler, R. Hardy, and S.F. Schlossman. 1981. Expression of cell surface markers after human B cell activation. Proc. Natl. Acad. Sci. U.S.A.
: 3848.PubMedCrossRefGoogle Scholar
Thorley-Lawson, D.A., R.T. Schooley, A.K. Bhan, and L.M. Nadler. 1982. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell
: 415.PubMedCrossRefGoogle Scholar
Freedman, A.S., A.W. Boyd, K.C. Anderson, D.C. Fisher, S.F. Schlossman, and L.M. Nadler. 1985. B5, a new B cell restricted activation antigen. J. Immunol.
: 2228.PubMedGoogle Scholar
Tsudo, M., T. Uchiyama, and H. Uchino. 1984. Expression of TAC antigen on activated normal human B cells. J. Exp. Med.
: 612.PubMedCrossRefGoogle Scholar
Boyd, A.W., D.C. Fisher, D. Fox, S.F. Schlossman, and L.M. Nadler. 1985. Structural and functional characterization of IL-2 receptors on activated B cells. J. Immunol.
: 2387.PubMedGoogle Scholar
Yokochi, T., R.D. Holly, and E.A. Clark. 1982. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt’s lymphomas. J. Immunol.
: 823.PubMedGoogle Scholar
Kerhl, J.H., A. Muraguchi, and A.S. Fauci. 1984. Differential expression of cell activation markers after stimulation of resting B lymphocytes. J. Immunol.
: 2857.Google Scholar
Reinherz, E.L., and S.F. Schlossman. 1980. The differentiation and functions of human T lymphocytes: a review. Cell
: 821.PubMedCrossRefGoogle Scholar
Stashenko, P., L.M. Nadler, R. Hardy, and S.F. Schlossman. 1980. Characterization of a human B lymphocyte-specific antigen. J. Immunol.
: 1678.PubMedGoogle Scholar
Todd, R.F. III, L.M. Nadler, and S.F. Schlossman. 1981. Antigens on human monocytes identified by monoclonal antibodies. J. Immunol.
: 1435.PubMedGoogle Scholar
Meuer, S.C., R.E. Hussey, M. Fabbi, D. Fox, O. Acuto, K.A. Fitzgerald, J.C. Hodgdon, J.P. Protentis, S.F. Schlossman, and E.L. Reinherz. 1984. An alternate pathway of T cell activation: A functional role for the 550Kd Til sheep erythrocyte receptor protein. Cell
: 897.PubMedCrossRefGoogle Scholar
Abramson, C.S., J.H. Kersey, and T.W. LeBien. 1981. A monoclonal anti-body (BA-1) reactive with cells of human B lymphocyte lineage. J. Immunol.
: 83.PubMedGoogle Scholar
Omary, M.B., I.S. Trowbridge, and H.A. Battifora. 1980. Human homologue of murine T200 glycoprotein. J. Exp. Med.
: 842.PubMedCrossRefGoogle Scholar
Nadler, L.M., P. Stashenko, R. Hardy, J.M. Pesando, E.J. Yunis, and S.F. Schlossman. 1981. Monoclonal antibodies defining serologically distinct HLA-D/DR related la-like antigen in man. Hum. Immunol.
: 77.CrossRefGoogle Scholar
Nadler, L.M., P. Stashenko, R. Hardy, A. van Agthoven, C. Terhorst, and S.F. Schlossman. 1981. Characterization of a human B cell-specific antigen (B2) distinct from Bl. J. Immunol.
: 1941.Google Scholar
Bhan, A.K., L.M. Nadler, P. Stashenko, and S.F. Schlossman. 1981. Stages of B cell differentiation in human lymphoid tissues. J. Exp. Med.
: 737.PubMedCrossRefGoogle Scholar
Hsu, S., and E.S. Jaffe. 1984. Phenotypic expression of B lymphocytes. 1. Identification with monoclonal antibodies in normal lymphoid tissues. Am. J. Pathol.
: 387.PubMedGoogle Scholar
Anderson, K.C., M.P. Bates, B.L. Slaughenhoupt, G.S. Pinkus, S.F. Schlossman, and L.M. Nadler. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood
: 1424.PubMedGoogle Scholar
Iida, K., L.M. Nadler, and V. Nussenzweig. 1983. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J. Exp. Med.
: 1021.PubMedCrossRefGoogle Scholar
Fingeroth, J.D., J.J. Weis, T.F. Tedder, J.L. Strominger, P.A. Biro, and D.T. Fearon. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U.S.A.
: 4510.PubMedCrossRefGoogle Scholar
© Springer-Verlag New York Inc. 1986